Overview

rhGH Therapy on Hepatic Drug Metabolism

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to understand the effect of rhGH therapy on hepatic drug metabolism in children with idiopathic growth hormone deficiency.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Louisville
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Caffeine
Dextromethorphan
Hormones
Criteria
Inclusion Criteria:

- Children ages 4 to 14 years with a height less than the 5th percentile for age and sex
or having a decelerated across two major percentiles (5th, 10th, 25th, 50th, 90th, and
95th) on standard pediatric growth curves, poor growth velocity (less than 5
centimeters/year), radiographic evidence of delayed bone age (i.e. greater than 1 SD
below the mean for chronological age) and a documented diagnosis of idiopathic growth
hormone deficiency [as determined by failure to raise serum GH concentrations 10
microgram/Liter following provocative testing with two growth hormone
secretagogues(e.g. insulin, arginine, or clonidine)].

- All subjects will be prepubertal, as determined by Tanner staging.

Exclusion Criteria:

- Children receiving medications known to induce or inhibit hepatic CYP1A2, NAT-2, XO,
CYP2D6 or CYP3A4 activity.

- Subjects with a history of smoking (including exposure to second hand smoke > 8 hours
per day) or illicit drug use.

- Subjects with a history of hepatic, renal, cardiac or thyroid disorders. Presence of
hepatic, renal, cardiac or thyroid disease will be established based on clinical
history and results of recent laboratory tests conducted as part of the routine
medical evaluation of children who are being considered for rhGH therapy.

- Children experiencing fever or acute viral illness

- Children who have a history of a hypersensitivity reaction to dextromethorphan or
caffeine

- Children who have received prior treatment with rhGH

- Children who are receiving corticosteroids or thyroid hormone